Avra Medical Robotics, Inc.

Ticker OTCQB: AVMR

Corporate Profile

as of April 11, 2018

Sector: Healthcare
Industry: Medical Devices and Technology
Website: www.avramedicalrobotics.com

Avra Medical Robotic Arm

Avra Medical Robotics, Inc. ("Avra", "Avra Medical", or the "Company") (OTCQB: AVMR) founded in 2015 and located in Orlando, Florida, is a developmental stage medical device and technology company focused on creating intelligent surgical robotic systems. CEO, Chairman and Founder, Barry F. Cohen, leads Avra in developing an autonomous intelligent surgical robotic system platform, initially to be used for dermatology and medical aesthetic uses. Further research and development activities followed by regulatory approvals could lead to broader future medical uses of the Avra surgical robotic system platform in performing other minimally invasive surgeries autonomously or semi-autonomously. Avra's objective is to produce safe, affordable and smaller autonomous surgical robotic systems that can be used not only in hospitals, but clinics and medical offices for minimal and non-invasive medical surgical procedures. Avra's intelligent surgical robotic system will allow doctors to deliver a more consistent, precise and predictable patient outcome than is available with current methods. In addition to surgeon reported benefits of robotic surgeries, patients report that robotic surgery offers improved recovery times, less pain, and better outcomes over traditional open surgery performed directly with human hands

The Company is collaborating with the University of Central Florida in a multi-year contract to develop its initial prototype of the robotic system including the controlling software. The robotic system is planned for use initially for dermatology and skin resurfacing procedures, such as microneedling, injections and laser therapies. However, once the Food and Drug Administration ("FDA") approvals are granted for these uses, Avra can seek regulatory approvals for other medical applications for its intelligent robotic system. The Company plans to initially target the large aesthetics and dermatology markets which currently include solutions such as Botox® and CO2 Lasers that are utilized for keratosis removal and for the treatment of lines, scarring, discoloration and other skin-related problems. Phase 2 research and development activities will address targeted drug delivery and other internal procedures that can benefit from Avra's advanced intelligence guidance system.

The way robots and humans interact will change with Avra's technology. Currently, robotically assisted surgery is by master slave systems in which the surgeon manually controls the instrument/s remotely. The Avra system will allow the surgeon to preprogram the procedure and review it in full simulation prior to the actual procedure being performed autonomously by the AVRA Medical robot arm. This will allow for consistently optimal results for both surgeons and patients. With Avra's aesthetics and dermatology system, the Avra facial mapping technology and IGS (Instrument Guidance System); the Company will be able to pinpoint tissue ir-regularities and precisely place the micro-needling or other instrument taking into consideration other factors such as depth, color and elasticity, with far greater accuracy than hand held devices. Much like a GPS with autopilot.

The Avra system is designed to work with existing FDA approved instruments and make them more precise and, combined with deep learning, deliver better outcomes. Six of Avra's previously submitted provisional patents were combined into one International Patent Application that brought together the various parts of the Company's "Intelligent Guidance System". The Patent covers the combination of a navigation system, including its various sensors such as distance and angle, different end effector mechanisms, with a medical robotic arm.

The Company fully owns the work product, including proprietary navigation algorithms, which was developed with the University of Central Florida. Avra Medical is slated to shift the already fast-growing aesthetics markets industry with its micro-needling technology and collagen regenerative options. According to a recent report by Grand View Research, the global aesthetic lasers annual market was valued at $508 million dollars and is expected to grow at a compounded annual growth rate ("CAGR") of 15.5%. Total expenditures on cosmetic surgeries in 2015 were $12 billion dollars in the US. The use of robotics is expected to be driven by the growing incidence rate of skin disorders and the new technology to cure them. Transparency Market Research states



AVRA Medical Robotics Technology

Recent Highlights

- Avra Medical is developing a software based autonomous surgical robotic system, which will allow surgeons to preprogram a procedure and review it fully simulated prior to the actual procedure. This allows surgeons to more accurately direct surgical devices and deliver improved outcomes.
- Avra Medical is developing aesthetics skin resurfacing and internal biopsy procedures. This will dramatically shift the way the procedures are performed through mapping and robotic stabilization.
- Avra Medical has a prestigious team of doctors, scientists and surgeons that are developing the robotics technology. Avra has partnered with the University of Central Florida in order to use its laboratory and professors for continued development of the software and electronics.
- Avra Medical filed as S-1 Registration Statement with the SEC, which became effective on July 31,2017. The Company is public; its shares will be listed via a 15C211 on the OTCQB Market. It is currently awaiting its trading symbol from FINRA.

Corporate Contact Information

Avra Medical Robotics, Inc.
Barry Cohen, CEO & Alex Clug, VP
3259 Progress Dr., Suite, 112
Orlando, FL 33826
Phone: 866-205-4430
www.avramedicalrobotics.com